BACKGROUND: Data from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) were used previously to develop a risk score calculator to predict 1-year survival. We evaluated prognostic implications of changes in the risk score and individual risk-score parameters over 12 months. METHODS: Patients were grouped by decreased, unchanged, or increased risk score from enrollment to 12 months. Kaplan-Meier estimates of subsequent 1-year survival were made based on change in the risk score during the initial 12 months of follow-up. Cox regression was used for multivariable analysis. RESULTS: Of 2,529 patients in the analysis cohort, the risk score was decreased in 800, unchanged in 959, and increased in 770 at 12 months post-enrollment. Six parameters (functional class, systolic blood pressure, heart rate, 6-minute walk distance, brain natriuretic peptide levels, and pericardial effusion) each changed sufficiently over time to improve or worsen risk scores in Z5% of patients. One-year survival estimates in the subsequent year were 93.7%, 90.3%, and 84.6% in patients with a decreased, unchanged, and increased risk score at 12 months, respectively. Change in risk score significantly predicted future survival, adjusting for risk at enrollment. Considering follow-up risk concurrently with risk at enrollment, follow-up risk was a much stronger predictor, although risk at enrollment maintained a significant effect on future survival. CONCLUSIONS: Changes in REVEAL risk scores occur in most patients with pulmonary arterial hypertension over a 12-month period and are predictive of survival. Thus, serial risk score assessments can identify changes in disease trajectory that may warrant treatment modifications.
Pulmonary arterial hypertension (PAH) is a progressive syndrome in which fibrotic and proliferative changes in pulmonary arteries lead to increased pulmonary vascular resistance, right heart failure, and eventual death. 1 The prognosis of patients with PAH has improved with modern therapies, but patient outcomes overall remain poor. Evidence-based clinical practice guidelines recommend the individualization of therapy based on disease severity to improve patient outcomes. 2 The Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (RE-VEAL) is a longitudinal registry that enrolled patients treated at pulmonary hypertension centers in the United States. 3 The data from REVEAL were used to develop a prognostic equation 4 and a simplified risk score calculator 5 to predict 1-year survival in patients with PAH. The REVEAL risk model has been validated statistically in a number of studies. [6] [7] [8] [9] The risk score calculator provides a prediction of prognosis based on the contribution of multiple variables, rather than a single variable, and predicts with good accuracy the survival of patients with PAH at 1 year. Although the calculator is designed to allow point-in-time assessment, none of the inputs to the calculator need to be strictly concurrent. Outside of clinical trials, having a full battery of assessments at the same time is very unusual. The variables entered into the calculator are based on the most recent assessment for each value, and the calculator can be updated any time any single variable is reassessed. This is an intended design feature of the calculator, although it must be assumed that the calculator allows for larger disparities between a patient's true underlying health state and the measured health state. This makes validation of the calculator for repeat assessments particularly important.
Whether serial recalculation of the REVEAL risk score is predictive of changes in survival over time remains unknown but warrants further exploration. Of the 19 variables included in the REVEAL prognostic equation, a few (e.g., gender or PAH sub-type) are not modifiable over time, and some have contended that these might mitigate the versatility of the risk score or that the effect of these immutable variables could negate the positive or negative effects of changes in other, modifiable variables such as the 6-minute walk distance (6MWD), brain natriuretic peptide (BNP), pericardial effusion status, renal functional status, or hemodynamic parameters. If that were the case, then recalculation of the risk score over time would not inform clinicians about the effects of interventions, which would suggest that efforts to improve the risk score and, hence, survival would be futile. In this analysis, we used data from patients with PAH enrolled in REVEAL to evaluate the prognostic implications of changes in the risk score, as well as the contributions of associated risk score variables to these changes, during a 12-month period.
Methods
A description of the design of REVEAL, including the inclusion and exclusion criteria, has been published previously. 3 In brief, the observational, prospective REVEAL registry involved 55 university-affiliated and community hospitals in the United States. 3 Patients who met the modified definition for World Health Organization Group 1 pulmonary hypertension 10 were enrolled consecutively beginning in March 2006 through December 2009. The Institutional Review Board at each participating center approved the protocol.
Data at enrollment and at reassessment used for the current analysis were based on the final study data from February 4, 2013. The analysis cohort included newly and previously diagnosed patients with Group 1 PAH aged Z19 years at diagnosis with pulmonary capillary wedge pressure r15 mm Hg at diagnosis and Z12 months of follow-up.
The REVEAL risk score at enrollment was calculated from the most recent assessments before the time of enrollment and recalculated from the most recent assessments before 12 months after enrollment. The analysis did not exclude patients with no new assessments performed in the first 12 months of follow-up. In these cases, the most recent value at enrollment remained the most recent value at follow-up. The absence of follow-up data for a patient who survived through 12 months and continued in the study was not a reason for exclusion from the analysis.
Among patients who survived to at least 365 days transplant free, Kaplan-Meier estimates were used to determine the subsequent 1-year survival for patients with an increased, decreased, or unchanged risk score during the initial 12 months of follow-up. Multivariable Cox regression was used to determine the effect on subsequent 1-year survival of the change in risk score over time and the recalculated score, controlling for risk score at enrollment (i.e., change and risk at enrollment were both included in the model). A single model was not fitted to include the 3 variables of risk score at enrollment, risk score at reassessment, and change in risk score, because if any 2 quantities are known, the third would be redundant. The log-rank test for comparison of Kaplan-Meier curves was used for calculating p values and the Wald test for assessing the significance of hazard ratios (HR). A p-value of o 0.05 was considered significant.
Results
REVEAL enrolled 3,515 patients, and 2,529 patients (80% female) were included in the current analysis ( Figure 1 ). The
Figure 1
Analysis of the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) population. PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension. analysis cohort was a mean age of 52.6 years at enrollment, and idiopathic PAH (IPAH; 47.1%) was the most common PAH etiology ( Table 1) .
The risk score calculated at enrollment in REVEAL used the most recent data up to and including the enrollment visit. The score was recalculated at 12 months, replacing any component of the risk score that had been reevaluated within the first 12 months of REVEAL follow-up with the most recent information up to and including the 12-month quarterly update. The change in the risk score at Month 12 as a function of the risk score at enrollment for all patients in the analysis cohort is reported in Table 2 .
At the time the risk score was recalculated, 959 (38%) had no change in the risk score, 800 (32%) had a decrease (improvement) in the risk score of at least 1 point, and 770 (30%) had an increase (worsening) in the risk score of at least 1 point. The newly diagnosed patients were more likely to have decreased (improved) scores (271 of 666 [41%]) compared with the previously diagnosed patients (529 of 1,863 [28%]). At enrollment, 58.9% and of newly diagnosed and 92.7% of previously diagnosed patients were receiving a PAH-specific medication, such as an endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, or prostanoid. During the first year of follow-up, 67% of newly diagnosed patients started a new PAH-specific medication. At the end of the first year of follow-up, 35% of newly diagnosed patients were receiving some form of combination therapy, and 25% were receiving parenteral prostanoids compared with 11% and 15% at enrollment, respectively. Among previously diagnosed patients, treatment changes in PAH-specific medications occurred for 59.9% of patients during the first year of follow-up, including new medication starts in 36.0%. At the end of the first year of follow-up, 54% of previously diagnosed patients were receiving some form of combination therapy, and 34% were receiving parenteral prostanoids compared with 44% and 31% at enrollment, respectively.
Changes in individual parameters of the risk score that resulted in an improved, unchanged, or worsened risk score are reported in Table 3 . The 6 individual parameters of New York Heart Association Functional Class, systolic blood pressure, heart rate, 6MWD, BNP levels, and pericardial effusion status improved sufficiently in 5.3% to 16.1% (Table 3 ) of patients to result in a decrease in the risk score at 12 months. These same 6 parameters also worsened sufficiently in 6.6% to 15.4% (Table 3 ) of patients to result in an increase in the risk score at 12 months.
When patients were stratified by change in the risk score, 1-year survival estimates from 12 months post-enrollment were 93.7% Ϯ 0.9% (p o 0.001) in patients whose risk score decreased (improved), 90.3% Ϯ 1.0% in patients whose risk score was unchanged, and 84.6% Ϯ 1.3% in patients whose risk score increased (worsened; Figure 2A ). An absence of follow-up assessments resulted in 4% of patients being included in the no-change group, and results did not differ when these patients were excluded in a sensitivity analysis. The differences in the estimates were also similar in the sub-set of newly diagnosed patients (92.6% Ϯ 1.6%, 85.3% Ϯ 2.4%, and 80.4% Ϯ 3.0% for the improved, unchanged, and worsened groups, respectively) and the sub-set of previously diagnosed patients (94.3% Ϯ 1.0%, 91.7% Ϯ 1.0%, and 85.8% Ϯ 1.4% for the improved, unchanged, and worsened groups, respectively). When all patients were stratified by risk score recalculated at 12 months, 1-year survival estimates from 12 months postenrollment were 97.3% Ϯ 0.5% (p o 0.001) in patients with a risk score of 0 to 7 (low risk), 93.0% Ϯ 1.3% in patients with a risk score of 8 (average risk), 85.3% Ϯ 1.9% in patients with a risk score of 9 (moderately high risk), 72.5% Ϯ 2.5% in patients with a risk score of 10 to 11 (high risk), and 50.2% Ϯ 5.0% in patients with a risk score of 12 to 15 (very high risk; Figure 2B ).
Multivariable Cox models were developed to assess the significance of the REVEAL risk score at enrollment, change in the risk score at reassessment at 12 months, and the risk score at reassessment as predictors of subsequent 1-year survival in REVEAL (Table 4 ). In one model adjusting for risk at enrollment, change in risk score significantly predicted subsequent 1-year survival, with HRs of 1.67 (95% confidence interval [CI], 1.41-1.99; p o 0.001) for worsened score and 0.57 (95% CI, 0.47-0.69; p o 0.001) for improved score. When follow-up risk was considered concurrently with risk at enrollment in another model, the risk score at enrollment (HR, 1.10; 95% CI, 1.04-1.15; p o 0.001) and the risk score at reassessment (HR, 1.40; 95% CI, 1.33-1.47; p o 0.001) were each significant predictors of survival, although the follow-up risk score was a much stronger predictor.
Discussion
The current analysis shows that the REVEAL prognostic equation and risk score calculator have prognostic value not only at a set point in time (e.g., at enrollment) but also when used for serial assessments. This utility allows clinicians to regularly reassess risk to identify patients in whom PAH is improving, stable, or progressing and to individualize therapy to meet the specific needs of patients. 4 Another recent cohort study has shown that changes in clinical variables in response to therapy may have important potential prognostic implications in patients with IPAH. 11 Our findings show that changes over time occurred in most patients even though changes in individual components of the risk score were relatively less frequent. There were, however, 6 parameters that changed sufficiently over time to improve the risk score in at least 5% of patients or to worsen the risk score in at least 6% of patients. That no single parameter was the primary source of change in the risk score (either improvement or worsening) highlights the importance of ongoing assessments of risk and using a multifactorial assessment, such as the REVEAL risk score calculator, to set goals.
Somewhat surprisingly, changes in renal insufficiency were very uncommon. This most likely reflects the use of a qualitative statement, abnormal vs normal, to define the variable instead of an absolute numeric value. Thus, a creatinine value could change from 2.5 mg/dl to 1.6 mg/dl and still be considered "abnormal" despite the improvement in the absolute number. However, we have noted in previous analyses that numeric creatinine cutoffs were equally prognostic, and it is likely that numeric depictions of creatinine or estimated glomerular filtration rate would be more sensitive to change.
More importantly, our findings strongly suggest that combined improvement in the modifiable parameters of the REVEAL risk score can overcome the risk conferred by nonmodifiable parameters and support the efforts of clinicians to lower overall patient risk. One model of survival found the recalculated risk score predicted subsequent 1-year survival better than the initial risk score, suggesting that a patient's place on the risk continuum after 12 months is a relatively better predictor of survival in the subsequent year. This also reinforces the potential benefits of ongoing risk assessment as a means to monitor patient response to treatment.
This analysis had several important limitations. Although risk is clearly multifactorial and modifiable, this analysis does not show which of the many risk factors associated with PAH are most important to modify or which treatments lead to such modifications. These are questions that are better answered with experimental designs rather than observational studies; however, more in-depth analyses of individual risk factors in both experimental and observational settings will also undoubtedly further our understanding. Because the risk score, as a composite instrument, has been repeatedly validated, we chose not to deconstruct the risk score into its component parts in this analysis. Although adding to the integrity of the validation, this choice also represents a limitation, because revisions could likely improve the risk score in the future.
The REVEAL risk score calculator is a simple tool that can aid clinicians in individualizing therapy according to One-year survival from 12 months post-enrollment (A) by change in the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) risk score and (B) by the REVEAL risk score recalculated at 12 months. each patient's risk and treatment goals. Indeed, all patients in REVEAL were actively managed, and treatment was changed in most over the course of the first year of followup. The use of serial risk score assessments may help identify patients with changes in disease severity and provide useful information when considering possible treatment modifications and subsequent evaluation of the relative success of those treatment changes. With additional validation, the risk score calculator used in the current analysis could be incorporated into routine clinical practice as a valuable tool to support clinicians in making treatment decisions best matched to individual patient's levels of risk as they evolve over time.
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